文献速递泌尿男性生殖肿瘤

晚期肾细胞癌患者基于免疫检查点抑制剂的联合治疗的前瞻性心血管监测:来自III期JAVELIN Renal 101试验的数据

Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial.
PubMed 文献 · J Clin Oncol · 2022-03-03

JAVELIN Renal 101试验前瞻性监测晚期肾细胞癌患者接受avelumab联合阿昔替尼或舒尼替尼治疗期间的心脏生物标志物与左心室射血分数(LVEF)。联合组主要不良心血管事件(MACE)发生率为7.1%,舒尼替尼组为3.9%;联合组基线肌钙蛋白T高者MACE风险升高(6/35 vs 7/135;相对风险3.31;95%CI 1.19-9.22)。结论认为基线肌钙蛋白T高者可能需更密切监测,不推荐对无症状患者常规监测LVEF。

要点

  • 联合组MACE发生31例(7.1%),舒尼替尼组17例(3.9%)。
  • 联合组基线肌钙蛋白T高者MACE风险升高(6/35 vs 7/135;相对风险3.31;95%CI 1.19-9.22)。
  • 不推荐对无症状患者常规监测LVEF。

核心结论

  • 接受免疫检查点抑制剂联合VEGFR抑制剂治疗且基线肌钙蛋白T水平高的患者可能需要更密切监测MACE。
  • 不推荐对无症状患者常规监测LVEF。

研究设计与样本

  • JAVELIN Renal 101是一项随机III期试验,评估avelumab联合阿昔替尼对比舒尼替尼治疗晚期肾细胞癌患者。
  • 该试验是首个在免疫检查点抑制剂联合VEGFR抑制剂治疗中纳入前瞻性连续心脏监测(LVEF和血清心脏生物标志物)的随机研究。

主要发现

  • MACE(定义为≥3级心血管不良事件)在联合组发生31例(7.1%),在舒尼替尼组发生17例(3.9%)。
  • 联合组基线肌钙蛋白T高者MACE发生6/35例,低者发生7/135例;相对风险3.31;95%CI 1.19-9.22。
  • 在舒尼替尼组未观察到上述关联。
  • 其他心血管基线危险因素和血清心脏生物标志物对MACE无显著预测作用,但联合组观察到血脂异常相关趋势。
  • 未观察到治疗期间常规监测LVEF与MACE相关的临床价值。

关键数值与推荐

  • MACE定义为≥3级心血管不良事件。
  • 联合组基线肌钙蛋白T高者相对低者的MACE相对风险为3.31(95%CI 1.19-9.22)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Both immune checkpoint inhibitors (ICIs) and vascular endothelial growth factor receptor (VEGFR) inhibitors are approved for advanced renal cell carcinoma treatment and can cause cardiovascular events (CVs); thus, combination therapy could lead to major adverse CV events (MACE). Cardiac serum biomarker assessment and imaging, including left ventricular ejection fraction (LVEF) monitoring, can be used to evaluate MACE. METHODS: To our knowledge, the JAVELIN Renal 101 trial, assessing avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma, is the first randomized study of ICI plus VEGFR inhibitor treatment to include prospective serial cardiac monitoring of LVEF and serum cardiac biomarkers. RESULTS: MACE (defined as grade ≥ 3 CV AEs) occurred in 31 patients (7.1%) in the combination arm and 17 patients (3.9%) in the sunitinib arm. Patients in the combination arm who had high baseline troponin T values were at higher risk of MACE versus patients with low values (MACE in 6/35 v 7/135, respectively; relative risk, 3.31; 95% CI, 1.19 to 9.22). This association was not observed in patients treated with sunitinib. Other CV baseline risk factors and serum cardiac biomarkers were not significantly predictive for MACE, although a trend toward an association with dyslipidemia was seen in the combination arm. No clinical value of on-treatment routine monitoring of LVEF in relation to MACE was observed. Although LVEF decline was significantly more frequent in the combination arm, most patients recovered, and decline was not associated with other significant cardiac events or symptoms. CONCLUSION: Patients with high baseline troponin T levels receiving ICI and VEGFR combinations may need to be monitored more closely for MACE. Routine monitoring of LVEF in asymptomatic patients is not recommended.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Rini BI, Moslehi JJ, Bonaca M, et al. Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial. J Clin Oncol. 2022. PMID: 35239416. doi:10.1200/JCO.21.01806

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。